nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Dactinomycin—uterine cancer	0.121	0.22	CbGbCtD
Leflunomide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0857	0.155	CbGbCtD
Leflunomide—ABCG2—Carboplatin—uterine cancer	0.0815	0.148	CbGbCtD
Leflunomide—ABCG2—Etoposide—uterine cancer	0.0684	0.124	CbGbCtD
Leflunomide—CYP1A2—Progesterone—uterine cancer	0.063	0.114	CbGbCtD
Leflunomide—CYP2C9—Progesterone—uterine cancer	0.0568	0.103	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—uterine cancer	0.0467	0.0846	CbGbCtD
Leflunomide—CYP1A2—Etoposide—uterine cancer	0.0282	0.0511	CbGbCtD
Leflunomide—DHODH—myometrium—uterine cancer	0.00781	0.0964	CbGeAlD
Leflunomide—DHODH—female reproductive system—uterine cancer	0.00455	0.0562	CbGeAlD
Leflunomide—DHODH—female gonad—uterine cancer	0.00414	0.0512	CbGeAlD
Leflunomide—AHR—myometrium—uterine cancer	0.00406	0.0502	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—uterine cancer	0.00374	0.0462	CbGeAlD
Leflunomide—PTK2B—decidua—uterine cancer	0.00367	0.0453	CbGeAlD
Leflunomide—PTK2B—renal system—uterine cancer	0.0036	0.0445	CbGeAlD
Leflunomide—AHR—uterine cervix—uterine cancer	0.00316	0.0391	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—uterine cancer	0.00307	0.038	CbGeAlD
Leflunomide—AHR—decidua—uterine cancer	0.00301	0.0372	CbGeAlD
Leflunomide—PTK2B—female reproductive system—uterine cancer	0.00288	0.0356	CbGeAlD
Leflunomide—AHR—endometrium—uterine cancer	0.00286	0.0354	CbGeAlD
Leflunomide—AHR—mammalian vulva—uterine cancer	0.00277	0.0342	CbGeAlD
Leflunomide—DHODH—lymph node—uterine cancer	0.00266	0.0329	CbGeAlD
Leflunomide—AHR—uterus—uterine cancer	0.00264	0.0326	CbGeAlD
Leflunomide—PTK2B—female gonad—uterine cancer	0.00262	0.0324	CbGeAlD
Leflunomide—PTK2B—vagina—uterine cancer	0.00261	0.0322	CbGeAlD
Leflunomide—AHR—female reproductive system—uterine cancer	0.00237	0.0293	CbGeAlD
Leflunomide—AHR—female gonad—uterine cancer	0.00216	0.0266	CbGeAlD
Leflunomide—AHR—vagina—uterine cancer	0.00214	0.0265	CbGeAlD
Leflunomide—PTK2B—lymph node—uterine cancer	0.00169	0.0208	CbGeAlD
Leflunomide—ABCG2—myometrium—uterine cancer	0.00158	0.0195	CbGeAlD
Leflunomide—AHR—lymph node—uterine cancer	0.00139	0.0171	CbGeAlD
Leflunomide—ABCG2—uterine cervix—uterine cancer	0.00123	0.0152	CbGeAlD
Leflunomide—ABCG2—decidua—uterine cancer	0.00117	0.0144	CbGeAlD
Leflunomide—ABCG2—endometrium—uterine cancer	0.00111	0.0137	CbGeAlD
Leflunomide—CYP1A2—renal system—uterine cancer	0.0011	0.0137	CbGeAlD
Leflunomide—ABCG2—mammalian vulva—uterine cancer	0.00107	0.0133	CbGeAlD
Leflunomide—ABCG2—uterus—uterine cancer	0.00102	0.0126	CbGeAlD
Leflunomide—CYP2C9—female reproductive system—uterine cancer	0.00084	0.0104	CbGeAlD
Leflunomide—ABCG2—female gonad—uterine cancer	0.000837	0.0103	CbGeAlD
Leflunomide—ABCG2—vagina—uterine cancer	0.000831	0.0103	CbGeAlD
Leflunomide—ABCG2—lymph node—uterine cancer	0.000538	0.00664	CbGeAlD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—uterine cancer	0.000341	0.0037	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—uterine cancer	0.000341	0.0037	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—PIK3CA—uterine cancer	0.000337	0.00365	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—uterine cancer	0.000332	0.00361	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKR1C1—uterine cancer	0.000331	0.0036	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000331	0.00359	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—KRAS—uterine cancer	0.000328	0.00356	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000327	0.00355	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EP300—uterine cancer	0.000326	0.00354	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—uterine cancer	0.000321	0.00348	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—uterine cancer	0.000311	0.00338	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	0.000309	0.00335	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—PIK3CA—uterine cancer	0.000301	0.00327	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PIK3CA—uterine cancer	0.000301	0.00327	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—uterine cancer	0.000301	0.00327	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.0003	0.00325	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000296	0.00321	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—RRM2—uterine cancer	0.000295	0.00321	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CDH1—uterine cancer	0.000294	0.00319	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—DCN—uterine cancer	0.000287	0.00311	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—KRAS—uterine cancer	0.000283	0.00307	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00028	0.00304	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—uterine cancer	0.000279	0.00303	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—EP300—uterine cancer	0.000274	0.00298	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—PTEN—uterine cancer	0.000272	0.00295	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP11A1—uterine cancer	0.00027	0.00293	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—PIK3CA—uterine cancer	0.000266	0.00289	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	0.000262	0.00285	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—uterine cancer	0.00026	0.00282	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—EP300—uterine cancer	0.000259	0.00281	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—SOCS3—uterine cancer	0.000256	0.00278	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000256	0.00278	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKR1C3—uterine cancer	0.000255	0.00277	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—CTNNB1—uterine cancer	0.000253	0.00275	CbGpPWpGaD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000253	0.00274	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—uterine cancer	0.000251	0.00273	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—uterine cancer	0.00025	0.00272	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—uterine cancer	0.00025	0.00271	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—uterine cancer	0.000246	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—uterine cancer	0.000246	0.00267	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—uterine cancer	0.000243	0.00264	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000243	0.00264	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—uterine cancer	0.00024	0.00261	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—CTNNB1—uterine cancer	0.000239	0.0026	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—uterine cancer	0.000233	0.00253	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000233	0.00253	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—CYP19A1—uterine cancer	0.000233	0.00253	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	0.000229	0.00248	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—uterine cancer	0.000223	0.00242	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—uterine cancer	0.000223	0.00242	CbGpPWpGaD
Leflunomide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.00022	0.00239	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—uterine cancer	0.00022	0.00239	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—uterine cancer	0.000219	0.00238	CbGpPWpGaD
Leflunomide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000218	0.00236	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—uterine cancer	0.000217	0.00236	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—uterine cancer	0.000217	0.00236	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CTNNB1—uterine cancer	0.000217	0.00235	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—uterine cancer	0.000215	0.00233	CbGpPWpGaD
Leflunomide—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	0.000213	0.00231	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—uterine cancer	0.000212	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PIK3CA—uterine cancer	0.000211	0.0023	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—uterine cancer	0.000211	0.00229	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—uterine cancer	0.000208	0.00226	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ERBB2—uterine cancer	0.000208	0.00226	CbGpPWpGaD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000208	0.00225	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—uterine cancer	0.000205	0.00222	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—uterine cancer	0.000201	0.00218	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—uterine cancer	0.0002	0.00217	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CYP19A1—uterine cancer	0.000199	0.00216	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—STK11—uterine cancer	0.000199	0.00216	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	0.000197	0.00214	CbGpPWpGaD
Leflunomide—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	0.000195	0.00212	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—uterine cancer	0.00019	0.00206	CbGpPWpGaD
Leflunomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000188	0.00204	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—uterine cancer	0.000188	0.00204	CbGpPWpGaD
Leflunomide—Hypokalaemia—Epirubicin—uterine cancer	0.000188	0.000682	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000188	0.000681	CcSEcCtD
Leflunomide—Discomfort—Etoposide—uterine cancer	0.000187	0.000678	CcSEcCtD
Leflunomide—Breast disorder—Epirubicin—uterine cancer	0.000187	0.000678	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.000186	0.000675	CcSEcCtD
Leflunomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000186	0.00202	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—uterine cancer	0.000185	0.00201	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—uterine cancer	0.000185	0.00201	CbGpPWpGaD
Leflunomide—Hypersensitivity—Dactinomycin—uterine cancer	0.000184	0.000669	CcSEcCtD
Leflunomide—Gastritis—Epirubicin—uterine cancer	0.000183	0.000664	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000182	0.00197	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Etoposide—uterine cancer	0.000181	0.000657	CcSEcCtD
Leflunomide—Infection—Etoposide—uterine cancer	0.00018	0.000653	CcSEcCtD
Leflunomide—Asthenia—Dactinomycin—uterine cancer	0.00018	0.000652	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—uterine cancer	0.000179	0.00194	CbGpPWpGaD
Leflunomide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000179	0.00194	CbGpPWpGaD
Leflunomide—Influenza—Epirubicin—uterine cancer	0.000179	0.000648	CcSEcCtD
Leflunomide—Asthma—Epirubicin—uterine cancer	0.000179	0.000648	CcSEcCtD
Leflunomide—Thrombocytopenia—Etoposide—uterine cancer	0.000177	0.000644	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PTEN—uterine cancer	0.000177	0.00192	CbGpPWpGaD
Leflunomide—Tachycardia—Etoposide—uterine cancer	0.000177	0.000642	CcSEcCtD
Leflunomide—Eosinophilia—Epirubicin—uterine cancer	0.000177	0.000642	CcSEcCtD
Leflunomide—Liver function test abnormal—Doxorubicin—uterine cancer	0.000176	0.000641	CcSEcCtD
Leflunomide—Skin disorder—Etoposide—uterine cancer	0.000176	0.000639	CcSEcCtD
Leflunomide—Dry skin—Doxorubicin—uterine cancer	0.000175	0.000636	CcSEcCtD
Leflunomide—Hyperhidrosis—Etoposide—uterine cancer	0.000175	0.000636	CcSEcCtD
Leflunomide—Pancreatitis—Epirubicin—uterine cancer	0.000175	0.000635	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PIK3CA—uterine cancer	0.000174	0.00189	CbGpPWpGaD
Leflunomide—Hypokalaemia—Doxorubicin—uterine cancer	0.000174	0.000631	CcSEcCtD
Leflunomide—Angina pectoris—Epirubicin—uterine cancer	0.000174	0.000631	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—PIK3CA—uterine cancer	0.000173	0.00188	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—uterine cancer	0.000173	0.00188	CbGpPWpGaD
Leflunomide—Breast disorder—Doxorubicin—uterine cancer	0.000173	0.000627	CcSEcCtD
Leflunomide—Anorexia—Etoposide—uterine cancer	0.000173	0.000627	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000172	0.000625	CcSEcCtD
Leflunomide—Bronchitis—Epirubicin—uterine cancer	0.000172	0.000623	CcSEcCtD
Leflunomide—Diarrhoea—Dactinomycin—uterine cancer	0.000171	0.000622	CcSEcCtD
Leflunomide—Pancytopenia—Epirubicin—uterine cancer	0.00017	0.000615	CcSEcCtD
Leflunomide—Hypotension—Etoposide—uterine cancer	0.000169	0.000614	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—uterine cancer	0.000169	0.000614	CcSEcCtD
Leflunomide—Neutropenia—Epirubicin—uterine cancer	0.000167	0.000606	CcSEcCtD
Leflunomide—Dysuria—Epirubicin—uterine cancer	0.000167	0.000606	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000166	0.000602	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—uterine cancer	0.000165	0.0006	CcSEcCtD
Leflunomide—Asthma—Doxorubicin—uterine cancer	0.000165	0.0006	CcSEcCtD
Leflunomide—Pollakiuria—Epirubicin—uterine cancer	0.000165	0.000599	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—PIK3CA—uterine cancer	0.000165	0.00179	CbGpPWpGaD
Leflunomide—Eosinophilia—Doxorubicin—uterine cancer	0.000164	0.000594	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—uterine cancer	0.000163	0.00178	CbGpPWpGaD
Leflunomide—Paraesthesia—Etoposide—uterine cancer	0.000163	0.00059	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—uterine cancer	0.000162	0.000588	CcSEcCtD
Leflunomide—Weight decreased—Epirubicin—uterine cancer	0.000162	0.000586	CcSEcCtD
Leflunomide—Dyspnoea—Etoposide—uterine cancer	0.000161	0.000586	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—uterine cancer	0.000161	0.00175	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—uterine cancer	0.000161	0.00175	CbGpPWpGaD
Leflunomide—Hyperglycaemia—Epirubicin—uterine cancer	0.000161	0.000585	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—uterine cancer	0.000161	0.000584	CcSEcCtD
Leflunomide—Pneumonia—Epirubicin—uterine cancer	0.00016	0.000581	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—uterine cancer	0.00016	0.00174	CbGpPWpGaD
Leflunomide—Infestation NOS—Epirubicin—uterine cancer	0.000159	0.000578	CcSEcCtD
Leflunomide—Infestation—Epirubicin—uterine cancer	0.000159	0.000578	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—uterine cancer	0.000159	0.000578	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—uterine cancer	0.000159	0.000577	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000158	0.000573	CcSEcCtD
Leflunomide—Rash—Dactinomycin—uterine cancer	0.000158	0.000573	CcSEcCtD
Leflunomide—Decreased appetite—Etoposide—uterine cancer	0.000157	0.000572	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—uterine cancer	0.000157	0.000569	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—uterine cancer	0.000156	0.000568	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000156	0.000568	CcSEcCtD
Leflunomide—Fatigue—Etoposide—uterine cancer	0.000156	0.000567	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	0.000156	0.00169	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Epirubicin—uterine cancer	0.000156	0.000566	CcSEcCtD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000156	0.00169	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000156	0.00169	CbGpPWpGaD
Leflunomide—Jaundice—Epirubicin—uterine cancer	0.000155	0.000563	CcSEcCtD
Leflunomide—Stomatitis—Epirubicin—uterine cancer	0.000155	0.000563	CcSEcCtD
Leflunomide—Pain—Etoposide—uterine cancer	0.000155	0.000562	CcSEcCtD
Leflunomide—Constipation—Etoposide—uterine cancer	0.000155	0.000562	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—uterine cancer	0.000155	0.000562	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—uterine cancer	0.000155	0.000562	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—uterine cancer	0.000154	0.000561	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—uterine cancer	0.000154	0.000561	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000154	0.000557	CcSEcCtD
Leflunomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000153	0.00166	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	0.000153	0.00166	CbGpPWpGaD
Leflunomide—Pollakiuria—Doxorubicin—uterine cancer	0.000153	0.000554	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—uterine cancer	0.000152	0.00165	CbGpPWpGaD
Leflunomide—Haematuria—Epirubicin—uterine cancer	0.000152	0.000551	CcSEcCtD
Leflunomide—Hepatobiliary disease—Epirubicin—uterine cancer	0.000151	0.000547	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—uterine cancer	0.00015	0.000545	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—uterine cancer	0.000149	0.000543	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—uterine cancer	0.000149	0.000542	CcSEcCtD
Leflunomide—DHODH—Metabolism—MTHFR—uterine cancer	0.000149	0.00162	CbGpPWpGaD
Leflunomide—Feeling abnormal—Etoposide—uterine cancer	0.000149	0.000542	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—PIK3CA—uterine cancer	0.000149	0.00162	CbGpPWpGaD
Leflunomide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000149	0.000541	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—uterine cancer	0.000149	0.00054	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—uterine cancer	0.000149	0.000539	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—uterine cancer	0.000148	0.000538	CcSEcCtD
Leflunomide—Gastrointestinal pain—Etoposide—uterine cancer	0.000148	0.000538	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—uterine cancer	0.000147	0.000535	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—uterine cancer	0.000147	0.000535	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.000146	0.00053	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—uterine cancer	0.000145	0.000526	CcSEcCtD
Leflunomide—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000144	0.000524	CcSEcCtD
Leflunomide—Urticaria—Etoposide—uterine cancer	0.000144	0.000522	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—uterine cancer	0.000144	0.000521	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—uterine cancer	0.000144	0.000521	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—uterine cancer	0.000144	0.000521	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—uterine cancer	0.000143	0.00052	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—uterine cancer	0.000143	0.00052	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—uterine cancer	0.000143	0.00052	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—uterine cancer	0.000143	0.00052	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—uterine cancer	0.000143	0.00052	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—uterine cancer	0.000143	0.000519	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—uterine cancer	0.000143	0.000519	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—uterine cancer	0.000142	0.00155	CbGpPWpGaD
Leflunomide—Pharyngitis—Epirubicin—uterine cancer	0.000142	0.000515	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AKR1B10—uterine cancer	0.000141	0.00153	CbGpPWpGaD
Leflunomide—Urinary tract disorder—Epirubicin—uterine cancer	0.000141	0.000512	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—uterine cancer	0.000141	0.000511	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—uterine cancer	0.00014	0.00051	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—uterine cancer	0.00014	0.00051	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—uterine cancer	0.00014	0.000509	CcSEcCtD
Leflunomide—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000139	0.000506	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—uterine cancer	0.000139	0.000504	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—uterine cancer	0.000138	0.000502	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—uterine cancer	0.000137	0.000499	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	0.000137	0.00149	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—uterine cancer	0.000136	0.00148	CbGpPWpGaD
Leflunomide—Erythema multiforme—Epirubicin—uterine cancer	0.000135	0.00049	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—uterine cancer	0.000134	0.00146	CbGpPWpGaD
Leflunomide—Eye disorder—Epirubicin—uterine cancer	0.000134	0.000485	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—uterine cancer	0.000133	0.000484	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	0.000133	0.00145	CbGpPWpGaD
Leflunomide—Haemoglobin—Doxorubicin—uterine cancer	0.000133	0.000482	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—uterine cancer	0.000133	0.000481	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—uterine cancer	0.000133	0.000481	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—uterine cancer	0.000132	0.00048	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—uterine cancer	0.000132	0.00048	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—uterine cancer	0.000131	0.000476	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000131	0.000474	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—uterine cancer	0.00013	0.000473	CcSEcCtD
Leflunomide—Asthenia—Etoposide—uterine cancer	0.00013	0.000472	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—uterine cancer	0.00013	0.000472	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—uterine cancer	0.00013	0.000471	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—uterine cancer	0.000129	0.000469	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	0.000129	0.0014	CbGpPWpGaD
Leflunomide—Mediastinal disorder—Epirubicin—uterine cancer	0.000129	0.000468	CcSEcCtD
Leflunomide—Chills—Epirubicin—uterine cancer	0.000128	0.000465	CcSEcCtD
Leflunomide—Pruritus—Etoposide—uterine cancer	0.000128	0.000465	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—uterine cancer	0.000128	0.000463	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	0.000127	0.00138	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—uterine cancer	0.000127	0.00138	CbGpPWpGaD
Leflunomide—Alopecia—Epirubicin—uterine cancer	0.000126	0.000458	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—uterine cancer	0.000125	0.000454	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—uterine cancer	0.000125	0.000454	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—uterine cancer	0.000124	0.000452	CcSEcCtD
Leflunomide—Diarrhoea—Etoposide—uterine cancer	0.000124	0.00045	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—uterine cancer	0.000124	0.000449	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—uterine cancer	0.000123	0.000445	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—uterine cancer	0.000123	0.000445	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—uterine cancer	0.000122	0.000442	CcSEcCtD
Leflunomide—Back pain—Epirubicin—uterine cancer	0.00012	0.000437	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	0.00012	0.0013	CbGpPWpGaD
Leflunomide—Dizziness—Etoposide—uterine cancer	0.00012	0.000435	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—uterine cancer	0.00012	0.000434	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—uterine cancer	0.000119	0.000434	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—uterine cancer	0.000119	0.000433	CcSEcCtD
Leflunomide—Chills—Doxorubicin—uterine cancer	0.000119	0.000431	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—uterine cancer	0.000118	0.000429	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—uterine cancer	0.000117	0.000426	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	0.000117	0.00127	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RNF43—uterine cancer	0.000117	0.00127	CbGpPWpGaD
Leflunomide—Alopecia—Doxorubicin—uterine cancer	0.000117	0.000424	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—uterine cancer	0.000116	0.000421	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—uterine cancer	0.000116	0.00126	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Epirubicin—uterine cancer	0.000115	0.000419	CcSEcCtD
Leflunomide—Vomiting—Etoposide—uterine cancer	0.000115	0.000418	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—uterine cancer	0.000115	0.000418	CcSEcCtD
Leflunomide—Anaemia—Epirubicin—uterine cancer	0.000115	0.000417	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000115	0.00124	CbGpPWpGaD
Leflunomide—Rash—Etoposide—uterine cancer	0.000114	0.000415	CcSEcCtD
Leflunomide—PTK2B—Immune System—IRF1—uterine cancer	0.000114	0.00124	CbGpPWpGaD
Leflunomide—Dermatitis—Etoposide—uterine cancer	0.000114	0.000414	CcSEcCtD
Leflunomide—Headache—Etoposide—uterine cancer	0.000113	0.000412	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—uterine cancer	0.000113	0.000412	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—uterine cancer	0.000113	0.000409	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—uterine cancer	0.000112	0.00122	CbGpPWpGaD
Leflunomide—Malaise—Epirubicin—uterine cancer	0.000112	0.000407	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—uterine cancer	0.000112	0.000406	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—uterine cancer	0.000111	0.000404	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—uterine cancer	0.000111	0.000404	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—uterine cancer	0.000111	0.000402	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	0.00011	0.0012	CbGpPWpGaD
Leflunomide—Palpitations—Epirubicin—uterine cancer	0.00011	0.000399	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000109	0.00118	CbGpPWpGaD
Leflunomide—Cough—Epirubicin—uterine cancer	0.000109	0.000394	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—uterine cancer	0.000108	0.000394	CcSEcCtD
Leflunomide—Nausea—Etoposide—uterine cancer	0.000108	0.000391	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—uterine cancer	0.000107	0.00039	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—INHBA—uterine cancer	0.000107	0.00116	CbGpPWpGaD
Leflunomide—Ill-defined disorder—Doxorubicin—uterine cancer	0.000107	0.000388	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—uterine cancer	0.000106	0.000386	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—uterine cancer	0.000106	0.000384	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—uterine cancer	0.000106	0.000384	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—uterine cancer	0.000106	0.000384	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000106	0.00115	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000106	0.00115	CbGpPWpGaD
Leflunomide—Anxiety—Epirubicin—uterine cancer	0.000106	0.000383	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000105	0.000382	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—uterine cancer	0.000105	0.00038	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—uterine cancer	0.000104	0.000377	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—uterine cancer	0.000104	0.000376	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—uterine cancer	0.000103	0.000375	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—uterine cancer	0.000103	0.000374	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000103	0.00111	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FBXW7—uterine cancer	0.000102	0.00111	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—uterine cancer	0.000102	0.00111	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—uterine cancer	0.000102	0.00111	CbGpPWpGaD
Leflunomide—Palpitations—Doxorubicin—uterine cancer	0.000102	0.000369	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—uterine cancer	0.000102	0.000369	CcSEcCtD
Leflunomide—ABCG2—Metabolism—NDUFB11—uterine cancer	0.000101	0.0011	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SRD5A2—uterine cancer	0.000101	0.0011	CbGpPWpGaD
Leflunomide—Infection—Epirubicin—uterine cancer	0.000101	0.000366	CcSEcCtD
Leflunomide—Cough—Doxorubicin—uterine cancer	0.0001	0.000365	CcSEcCtD
Leflunomide—Nervous system disorder—Epirubicin—uterine cancer	9.96e-05	0.000361	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—uterine cancer	9.94e-05	0.000361	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—uterine cancer	9.94e-05	0.000361	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—uterine cancer	9.91e-05	0.00036	CcSEcCtD
Leflunomide—Skin disorder—Epirubicin—uterine cancer	9.86e-05	0.000358	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—uterine cancer	9.81e-05	0.000356	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—uterine cancer	9.8e-05	0.000356	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—uterine cancer	9.8e-05	0.000356	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—uterine cancer	9.8e-05	0.000356	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	9.79e-05	0.00106	CbGpPWpGaD
Leflunomide—Anxiety—Doxorubicin—uterine cancer	9.77e-05	0.000355	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—uterine cancer	9.74e-05	0.00106	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	9.73e-05	0.000353	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—uterine cancer	9.68e-05	0.000351	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—uterine cancer	9.68e-05	0.000351	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AKR1C1—uterine cancer	9.64e-05	0.00105	CbGpPWpGaD
Leflunomide—Dry mouth—Doxorubicin—uterine cancer	9.58e-05	0.000348	CcSEcCtD
Leflunomide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	9.49e-05	0.00103	CbGpPWpGaD
Leflunomide—Hypotension—Epirubicin—uterine cancer	9.49e-05	0.000344	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—uterine cancer	9.39e-05	0.000341	CcSEcCtD
Leflunomide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	9.36e-05	0.00102	CbGpPWpGaD
Leflunomide—Infection—Doxorubicin—uterine cancer	9.33e-05	0.000339	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	9.29e-05	0.00101	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	9.29e-05	0.00101	CbGpPWpGaD
Leflunomide—Musculoskeletal discomfort—Epirubicin—uterine cancer	9.25e-05	0.000336	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—uterine cancer	9.21e-05	0.000334	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—uterine cancer	9.2e-05	0.000334	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—uterine cancer	9.18e-05	0.000333	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—uterine cancer	9.17e-05	0.000333	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—uterine cancer	9.12e-05	0.000331	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—uterine cancer	9.12e-05	0.000331	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—uterine cancer	9.08e-05	0.00033	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—uterine cancer	9.05e-05	0.000329	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—uterine cancer	8.95e-05	0.000325	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—uterine cancer	8.94e-05	0.000324	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—uterine cancer	8.83e-05	0.00032	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	8.8e-05	0.000955	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—uterine cancer	8.79e-05	0.000954	CbGpPWpGaD
Leflunomide—Hypotension—Doxorubicin—uterine cancer	8.78e-05	0.000319	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—uterine cancer	8.76e-05	0.000318	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—uterine cancer	8.75e-05	0.000318	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	8.69e-05	0.000943	CbGpPWpGaD
Leflunomide—Constipation—Epirubicin—uterine cancer	8.68e-05	0.000315	CcSEcCtD
Leflunomide—Pain—Epirubicin—uterine cancer	8.68e-05	0.000315	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	8.56e-05	0.000311	CcSEcCtD
Leflunomide—Insomnia—Doxorubicin—uterine cancer	8.5e-05	0.000308	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—uterine cancer	8.43e-05	0.000306	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—uterine cancer	8.37e-05	0.000304	CcSEcCtD
Leflunomide—PTK2B—Immune System—SOCS3—uterine cancer	8.37e-05	0.000909	CbGpPWpGaD
Leflunomide—Feeling abnormal—Epirubicin—uterine cancer	8.37e-05	0.000304	CcSEcCtD
Leflunomide—DHODH—Metabolism—PTEN—uterine cancer	8.3e-05	0.000902	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Epirubicin—uterine cancer	8.3e-05	0.000301	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	8.28e-05	0.000899	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	8.28e-05	0.000899	CbGpPWpGaD
Leflunomide—Dyspepsia—Doxorubicin—uterine cancer	8.27e-05	0.0003	CcSEcCtD
Leflunomide—Decreased appetite—Doxorubicin—uterine cancer	8.17e-05	0.000296	CcSEcCtD
Leflunomide—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	8.11e-05	0.000881	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.11e-05	0.000294	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—uterine cancer	8.1e-05	0.000294	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PIK3CA—uterine cancer	8.07e-05	0.000876	CbGpPWpGaD
Leflunomide—Urticaria—Epirubicin—uterine cancer	8.07e-05	0.000293	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—uterine cancer	8.03e-05	0.000292	CcSEcCtD
Leflunomide—Pain—Doxorubicin—uterine cancer	8.03e-05	0.000292	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—uterine cancer	8.03e-05	0.000291	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—uterine cancer	8.03e-05	0.000291	CcSEcCtD
Leflunomide—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	8e-05	0.000868	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—EP300—uterine cancer	7.92e-05	0.00086	CbGpPWpGaD
Leflunomide—Feeling abnormal—Doxorubicin—uterine cancer	7.74e-05	0.000281	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—uterine cancer	7.68e-05	0.000279	CcSEcCtD
Leflunomide—Hypersensitivity—Epirubicin—uterine cancer	7.48e-05	0.000272	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	7.48e-05	0.000812	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—uterine cancer	7.47e-05	0.000811	CbGpPWpGaD
Leflunomide—Urticaria—Doxorubicin—uterine cancer	7.46e-05	0.000271	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—uterine cancer	7.43e-05	0.00027	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—uterine cancer	7.43e-05	0.00027	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—AKR1C3—uterine cancer	7.42e-05	0.000806	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKR1B1—uterine cancer	7.3e-05	0.000793	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—STAR—uterine cancer	7.3e-05	0.000793	CbGpPWpGaD
Leflunomide—Asthenia—Epirubicin—uterine cancer	7.28e-05	0.000264	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PGR—uterine cancer	7.23e-05	0.000785	CbGpPWpGaD
Leflunomide—Pruritus—Epirubicin—uterine cancer	7.18e-05	0.000261	CcSEcCtD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.08e-05	0.000768	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.08e-05	0.000768	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FGFR2—uterine cancer	6.98e-05	0.000758	CbGpPWpGaD
Leflunomide—Diarrhoea—Epirubicin—uterine cancer	6.95e-05	0.000252	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—uterine cancer	6.92e-05	0.000251	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—YWHAE—uterine cancer	6.9e-05	0.000749	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—uterine cancer	6.74e-05	0.000245	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—uterine cancer	6.71e-05	0.000244	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—uterine cancer	6.65e-05	0.000241	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—FBXW7—uterine cancer	6.61e-05	0.000718	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—uterine cancer	6.45e-05	0.000234	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—uterine cancer	6.43e-05	0.000233	CcSEcCtD
Leflunomide—Rash—Epirubicin—uterine cancer	6.4e-05	0.000232	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—uterine cancer	6.4e-05	0.000232	CcSEcCtD
Leflunomide—Headache—Epirubicin—uterine cancer	6.36e-05	0.000231	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	6.36e-05	0.00069	CbGpPWpGaD
Leflunomide—Dizziness—Doxorubicin—uterine cancer	6.21e-05	0.000226	CcSEcCtD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	6.08e-05	0.00066	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—uterine cancer	6.03e-05	0.000219	CcSEcCtD
Leflunomide—Vomiting—Doxorubicin—uterine cancer	5.97e-05	0.000217	CcSEcCtD
Leflunomide—Rash—Doxorubicin—uterine cancer	5.92e-05	0.000215	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—uterine cancer	5.92e-05	0.000215	CcSEcCtD
Leflunomide—Headache—Doxorubicin—uterine cancer	5.88e-05	0.000214	CcSEcCtD
Leflunomide—DHODH—Metabolism—PIK3CA—uterine cancer	5.86e-05	0.000636	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—STK11—uterine cancer	5.78e-05	0.000628	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—POLD1—uterine cancer	5.73e-05	0.000622	CbGpPWpGaD
Leflunomide—Nausea—Doxorubicin—uterine cancer	5.58e-05	0.000203	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—SOCS3—uterine cancer	5.41e-05	0.000588	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKR1C1—uterine cancer	5.36e-05	0.000582	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDH1—uterine cancer	5.19e-05	0.000564	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.19e-05	0.000564	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN2B—uterine cancer	5.18e-05	0.000563	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SRD5A2—uterine cancer	5.1e-05	0.000554	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—NDUFB11—uterine cancer	5.1e-05	0.000554	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1R—uterine cancer	5.03e-05	0.000546	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.95e-05	0.000538	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—uterine cancer	4.79e-05	0.00052	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—RRM2—uterine cancer	4.78e-05	0.000519	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SMAD3—uterine cancer	4.73e-05	0.000514	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.68e-05	0.000508	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—DCN—uterine cancer	4.64e-05	0.000503	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FGFR2—uterine cancer	4.51e-05	0.00049	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ERBB2—uterine cancer	4.38e-05	0.000476	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP11A1—uterine cancer	4.37e-05	0.000474	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SRD5A2—uterine cancer	4.36e-05	0.000473	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—NDUFB11—uterine cancer	4.36e-05	0.000473	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.23e-05	0.00046	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKR1C3—uterine cancer	4.13e-05	0.000448	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—uterine cancer	4.06e-05	0.000441	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4e-05	0.000434	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ESR1—uterine cancer	3.86e-05	0.000419	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—uterine cancer	3.83e-05	0.000416	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PTEN—uterine cancer	3.74e-05	0.000406	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKR1B1—uterine cancer	3.69e-05	0.0004	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—STAR—uterine cancer	3.69e-05	0.0004	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.64e-05	0.000396	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—uterine cancer	3.56e-05	0.000387	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCL2—uterine cancer	3.4e-05	0.000369	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—uterine cancer	3.33e-05	0.000362	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—STK11—uterine cancer	3.21e-05	0.000349	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CYP19A1—uterine cancer	3.21e-05	0.000349	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—STAR—uterine cancer	3.15e-05	0.000342	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKR1B1—uterine cancer	3.15e-05	0.000342	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.11e-05	0.000338	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—POLD1—uterine cancer	2.89e-05	0.000314	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—uterine cancer	2.87e-05	0.000312	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ERBB2—uterine cancer	2.83e-05	0.000308	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKR1C1—uterine cancer	2.71e-05	0.000294	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL8—uterine cancer	2.69e-05	0.000292	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PIK3CA—uterine cancer	2.64e-05	0.000286	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—uterine cancer	2.62e-05	0.000285	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—uterine cancer	2.48e-05	0.000269	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—POLD1—uterine cancer	2.47e-05	0.000268	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—uterine cancer	2.44e-05	0.000265	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PTEN—uterine cancer	2.42e-05	0.000262	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—MTHFR—uterine cancer	2.41e-05	0.000262	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—RRM2—uterine cancer	2.41e-05	0.000262	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—DCN—uterine cancer	2.34e-05	0.000254	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKR1C1—uterine cancer	2.31e-05	0.000251	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—uterine cancer	2.3e-05	0.00025	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP11A1—uterine cancer	2.21e-05	0.00024	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—uterine cancer	2.18e-05	0.000237	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—uterine cancer	2.16e-05	0.000234	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—uterine cancer	2.15e-05	0.000234	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKR1C3—uterine cancer	2.08e-05	0.000226	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—RRM2—uterine cancer	2.06e-05	0.000224	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—DCN—uterine cancer	2e-05	0.000217	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP11A1—uterine cancer	1.89e-05	0.000205	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—uterine cancer	1.86e-05	0.000201	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKR1C3—uterine cancer	1.78e-05	0.000193	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PIK3CA—uterine cancer	1.7e-05	0.000185	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—uterine cancer	1.65e-05	0.000179	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—STK11—uterine cancer	1.62e-05	0.000176	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.62e-05	0.000176	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—uterine cancer	1.58e-05	0.000171	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.52e-05	0.000165	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.45e-05	0.000158	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—uterine cancer	1.39e-05	0.000151	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—STK11—uterine cancer	1.39e-05	0.000151	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.39e-05	0.000151	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PTEN—uterine cancer	1.34e-05	0.000146	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.3e-05	0.000141	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—uterine cancer	1.28e-05	0.000139	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.24e-05	0.000135	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—MTHFR—uterine cancer	1.22e-05	0.000132	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.07e-05	0.000117	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—MTHFR—uterine cancer	1.04e-05	0.000113	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PIK3CA—uterine cancer	9.48e-06	0.000103	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	9.19e-06	9.97e-05	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—uterine cancer	7.74e-06	8.41e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PTEN—uterine cancer	6.79e-06	7.37e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—uterine cancer	6.47e-06	7.03e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PTEN—uterine cancer	5.8e-06	6.3e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—uterine cancer	5.53e-06	6e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PIK3CA—uterine cancer	4.79e-06	5.2e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PIK3CA—uterine cancer	4.09e-06	4.44e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—uterine cancer	3.91e-06	4.25e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—uterine cancer	3.34e-06	3.63e-05	CbGpPWpGaD
